Therapeutic Potential of Probiotics: A Ray of Hope or Nightmare?

Author(s): Malika Arora, Navdeep Kaur, Parveen Bansal*, Ashish Baldi.

Journal Name: Applied Clinical Research, Clinical Trials and Regulatory Affairs

Volume 6 , Issue 1 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: The role of various probiotic microorganisms with a particular emphasis on their therapeutic use in human health and disease has been highlighted by diverse scientific research reports. Due to improvement and introduction of new technologies useful to understand the functionality and mode of action of probiotics with respect to nutritional as well as health perspectives, the research on probiotics has recently grabbed the attention of manufacturers, regulators as well as researchers. Currently there are clinical trial based evidences to support the effectiveness of probiotic interventions in various types of diarrheal diseases, chronic gastrointestinal inflammatory disorders, hypercholesterolemia, hypertension, diabetes, oral health etc. However, due to inadequate awareness about risks associated with the probiotics amongst physicians, regulatory authorities, consumers and manufacturers many attributes like quality, safety and efficacy require urgent attention. At the same time regulatory guidelines for these products face ambiguity. So, it is of utmost importance to evaluate the true status of probiotic products available in market with respect to all above mentioned parameters and to formulate harmonized regulatory guidelines for the manufacturing of probiotic products.

Conclusion: The present compilation aims to highlight the progression of probiotic research related to therapeutic potentials of probiotics, clinical trials on probiotics, risks and regulatory concerns associated with probiotics and their use.

Keywords: Probiotics, therapeutic uses, regulatory control, dietary supplements, clinical trials, probiotic intervention.

[1]
Whitman WB, Coleman DC, Wiebe WJ. Prokaryotes: The unseen majority. Proc Natl Acad Sci 1998; 95(12): 6578-83.
[2]
Singh K, Kallali B, Kumar A, et al. Probiotics: A review. Asian Pac J Trop Biomed 2011; 1(2): S287-90.
[3]
Ganguly NK, Bhattacharya SK, Sesikeran B, et al. ICMR-DBT guidelines for evaluation of probiotics in food. Indian J Med Res 2011; 134(1): 22-5.
[4]
Arora T, Singh S, Sharma RK. Probiotics: Interaction with gut microbiome and antiobesity potential. J Nutr 2002; 29(4): 591-6.
[5]
Gill HS, Rutherfurd KJ. Viability and dose-response studies on the effects of the immune enhancing lactic acid bacterium Lactobacillus rhamnosus in mice. Br J Nutr 2001; 86(02): 285-9.
[6]
Sudha MR, Chauhan P, Dixit K, et al. Probiotics as complementary therapy for hypercholesterolemia Biol Med 20019; 1(4): 1-3.
[7]
Hasler CM. Functional foods: Benefits, concerns and challenges- A position paper from the American Council on Science and Health. J Nutr 2002; 132(12): 3772-8.
[8]
Arora M, Baldi A. Good manufacturing practice regulations for probiotic based pharmaceuticals: Current scenario and suggestive recommendations. Appl Clin Res Clin Trials Regul Aff 2013; 2(3): 165-75.
[9]
Azizpour K, Bahrambeygi S, Mahmoodpour S, et al. History and basic of probiotics. Int J Biol Sci 2009; 4(4): 409-26.
[10]
Tissier H. Repartition des microbes dans l’intestin du nourisson. Ann Inst Pasteur 1905; 19: 109-13.
[11]
Gordon S. Elie Metchnikoff: Father of natural immunity. Eur J Immunol 2008; 38(12): 3257-64.
[12]
Goldin BR. Probiotics and health: From history to future. Probiotics and Health Claims. In: Kneifel W, Salminen S, Eds. 1st ed. Oxford: Wiley-Blackwell 2011.
[13]
Anukam KC, Reid G. Probiotics: 100 years (1907-2007) after Elie Metchnikoff’s observation. Communicating current research and educational topics and trends. Appl Microbiol 2007; 1: 466-74.
[14]
Parker RB. Probiotics, the other half of the antibiotic story. Anim Nutr Health 1974; 29(29): 4-8.
[15]
AFRC RF. Probiotics in man and animals. J Appl Microbiol 1989; 66(5): 365-78.
[16]
Joint FAO/WHO Working Group. Guidelines for the evaluation of probiotics in food. London: World Health Organization ON Canada: Food and Agriculture Organization 2002.
[17]
Draft Food Safety and Standards (Food or Health Supplement, Nutraceuticals, Food for Special Dietary uses, Food for Special Medical Purposes, Functional Foods and Novel Foods) Regulation, 2015. [Cited: 23 June 2017]. Available from: old.fssai.gov.in/Out-reach/DraftforConsultations.aspx
[18]
Sreeja V, Prajapati JB. Probiotic formulations: Application and status as pharmaceuticals- A review. Probiotics Antimicrob Proteins 2013; 5(2): 81-91.
[19]
Collins MD, Gibson GR. Probiotics, prebiotics, and synbiotics: Approaches for modulating the microbial ecology of the gut. Am J Clin Nutr 1999; 69(5): 1052s-7s.
[20]
Price EC. Does the FDA have authority to regulate human cloning. Harv JL Tech 1997; 611: 619.
[21]
Sharma S, Arora M, Baldi A. Probiotics in India: Current status and future prospects. Pharm Aspire 2013; 1: 4-68.
[22]
McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2011; 101(4): 812-22.
[23]
Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science 2006; 308(5728): 1635-8.
[24]
Sharma B, Srivastava S, Singh N, Sachdev V, Kapur S, Saraya A. Role of probiotics on gut permeability and endotoxemia in patients with acute pancreatitis: A double-blind randomized controlled trial. J Clin Gastroenterol 2011; 45(5): 442-8.
[25]
Greenbaum A, Aryana KJ. Effect of honey a natural sweetener with several medicinal properties on the attributes of a frozen dessert containing the probiotic Lactobacillus acidophilus. Open J Med Microbiol 2013; 3(2): 95-9.
[26]
Gill HS, Guarner F. Probiotics and human health: A clinical perspective. Postgrad Med J 2006; 80(947): 516-26.
[27]
Sudha MR, Chauhan P, Dixit K, et al. Probiotics as complementary therapy for hypercholesterolemia. Biol Med 2009; 1(4): 1-3.
[28]
Kumar M, Nagpal R, Kumar R, et al. Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases. Exp Diabetes Res 2002.
[http://dx.doi.org/10.1155/2012/902917]
[29]
Suvarna VC, Boby VU. Probiotics in human health: A current assessment. Curr Sci 2002; 88(11): 1744-8.
[30]
Jiang T, Mustapha A, Savaiano DA. Improvement of lactose digestion in humans by ingestion of unfermented milk containing Bifidobacterium longum. J Dairy Sci 1996; 79(5): 750-7.
[31]
Walker WA, Duffy LC. Diet and bacterial colonization: Role of probiotics and prebiotics. J Nutr Biochem 1998; 9(12): 668-75.
[32]
Casas IA, Dobrogosz WJ. Validation of the probiotic concept: Lactobacillus reuteri confers broad-spectrum protection against disease in humans and animals. Microb Ecol Health Dis 2000; 12(4): 247-85.
[33]
Aattouri N, Bouras M, Tome D, et al. Oral ingestion of lactic-acid bacteria by rats increases lymphocyte proliferation and interferon-γ production. Br J Nutr 2002; 87(04): 367-73.
[34]
Goldin BR, Gorbach SL, Saxelin M, et al. Survival of Lactobacillus species (strain GG) in human gastrointestinal tract. Dig Dis Sci 1992; 37(1): 121-8.
[35]
Kumar K, Sastry N, Polaki H, Mishra V. Colon cancer prevention through probiotics: An overview. J Cancer Sci Ther 2015; 7(3): 81-92.
[36]
Neha A, Kamaljit S, Ajay B, et al. Probiotic: As effective treatment of diseases. Res Rev J Pharm Pharm Sci 2012; 3: 96-101.
[37]
Bonifait L, Grenier D. Cranberry polyphenols: Potential benefits for dental caries and periodontal disease. J Can Dent Assoc 2009; 76: a130.
[38]
Haukioja A. Probiotics and oral health. Eur J Dent 2010; 4(3): 348-55.
[39]
Iannitti T, Palmieri B. Therapeutical use of probiotic formulations in clinical practice. Clin Nutr 2010; 29(6): 701-25.
[40]
Kaur IP, Chopra K, Saini A. Probiotics: Potential pharmaceutical applications. Eur J Pharm Sci 2009; 15(1): 1-9.
[41]
Frei R, Akdis M, O’Mahony L. Prebiotics, probiotics, synbiotics, and the immune system: Experimental data and clinical evidence. Curr Opin Gastroenterol 2015; 31(2): 153-8.
[42]
Wadher KJ, Mahore JG, Umekar MJ. Probiotics: Living medicines in health maintenance and disease prevention. Inter J Pharma Bio Sci 2010; (3): 1-9.
[43]
Lye HS, Kuan CY, Ewe JA, et al. The improvement of hypertension by probiotics: Effects on cholesterol, diabetes, renin, and phytoestrogens. Int J Mol Sci 2009; 10(9): 3755-75.
[44]
Parvez S, Malik KA, Ah Kang S, et al. Probiotics and their fermented food products are beneficial for health. Appl Microbiol Biotechnol 2006; 100(6): 1171-85.
[45]
Correia MI, Liboredo JC, Consoli ML. The role of probiotics in gastrointestinal surgery. Open Nutr J 2016; 28(3): 230-4.
[46]
Uccello M, Malaguarnera G, Basile F, et al. Potential role of probiotics on colorectal cancer prevention. BMC Surg 2012; 12(1): S35.
[47]
Gawrońska A, Dziechciarz P, Horvath A, et al. A randomized double‐blind placebo‐controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther 2007; 25(2): 177-84.
[48]
Hamilton-Miller JM. The role of probiotics in the treatment and prevention of Helicobacter pylori infection. Int J Antimicrob Agents 2003; 22(4): 360-6.
[49]
Yun SI, Park HO, Kang JH. Effect of Lactobacillus gasseri BNR17 on blood glucose levels and body weight in a mouse model of type 2 diabetes. Appl Microbiol Biotechnol 2009; 107(5): 1681-6.
[50]
De Angelis M, Rizzello CG, Fasano A, et al. VSL# 3 probiotic preparation has the capacity to hydrolyze gliadin polypeptides responsible for celiac sprue probiotics and gluten intolerance. Biochimica et Biophysica Acta (BBA)-. Mol Basis Dis 2006; 1762(1): 80-93.
[51]
Saavedra JM, Dattilo AM. Early development of intestinal microbiota: Implications for future health. Gastrointest Endosc Clin N Am 2012; 41(4): 717-31.
[52]
Lee J, Bielory L. Probiotics for the treatment or prevention of eczema. J Allergy Clin Immunol 2009; 123(1): 266-7.
[53]
Hao Q, Lu Z, Dong BR, et al. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev 2011; 9(9): 266-7.
[54]
Molina VC, Medici M, Taranto MP, et al. Lactobacillus reuteri CRL 1098 prevents side effects produced by a nutritional vitamin B12 deficiency. Appl Microbiol Biotechnol 2009; 106(2): 467-73.
[55]
Navdeep S, Malika A, Ashish B. Market survey of pharmacist’s beliefs on clinical use of probiotics: Assessment of current practice patterns. Pharm Aspire 2015; (5):18-9.
[56]
Selinger CP, Bell A, Cairns A, et al. Probiotic VSL# 3 prevents antibiotic-associated diarrhoea in a double-blind, randomized, placebo-controlled clinical trial. J Hosp Infect 2013; 84(2): 159-65.
[57]
Mastromarino P, Vitali B, Mosc L. Bacterial vaginosis: A review on clinical trials with probiotics. New Microbiol 2013; 36(3): 229-38.
[58]
Dai C, Zhao DH, Jiang M. VSL# 3 probiotics regulate the intestinal epithelial barrier in vivo and in vitro via the p38 and ERK signaling pathways. Int J Mol Med 2013; 29(2): 202-8.
[59]
Salminen S, Isolauri E, Salminen E. Clinical uses of probiotics for stabilizing the gut mucosal barrier: Successful strains and future challenges. Antonie van Leeuwenhoek 1996; 70(2): 347-58.
[60]
Thang CL, Boye JI, Zhao X. Low doses of allergen and probiotic supplementation separately or in combination alleviate allergic reactions to cow β-lactoglobulin in mice. J Nutr 2013; 143(2): 136-41.
[61]
Shahani KM, Ayebo AD. Role of dietary lactobacilli in gastrointestinal microecology. Am J Clin Nutr 1980; 33(11): 2448-57.
[62]
Klatt NR, Canary LA, Sun X, et al. Probiotic/prebiotic supplementation of antiretrovirals improves gastrointestinal immunity in SIV-infected macaques. J Clin Invest 2013; 123(2): 903-7.
[63]
Black F, Einarsson K, Lidbeck A, et al. Effect of lactic acid producing bacteria on the human intestinal microflora during ampicillin treatment. J Infect Dis 1991; 23(2): 247-54.
[64]
Sanaie S, Ebrahimi-Mameghani M, Mahmoodpoor A, et al. Effect of a probiotic preparation (VSL# 3) on cardiovascular risk parameters in critically-ill patients. J Thorac 2013; 5(2): 67-70.
[65]
Rafter J, Bennett M, Caderni G, et al. Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients. Am J Clin Nutr 2007; 85(2): 488-96.
[66]
Dharmani P, De Simone C, Chadee K. The probiotic mixture VSL# 3 accelerates gastric ulcer healing by stimulating vascular endothelial growth factor. PLoS One 2013; 8(3): e58671.
[67]
Mathur S, Singh R. Antibiotic resistance in food lactic acid bacteria- A review. Int J Food Microbiol 2005; 105(3): 281-95.
[68]
Senok AC, Ismaeel AY, Botta GA. Probiotics: Facts and myths. Clin Microbiol Infect 2005; 11(12): 958-66.
[69]
Deitch EA, Maejima K, Berg R. Effect of oral antibiotics and bacterial overgrowth on the translocation of the GI tract microflora in burned rats. J Trauma Acute Care Surg 1985; 25(5): 385-92.
[70]
Berg RD. The indigenous gastrointestinal microflora. Trends Microbiol 1996; 4(11): 430-5.
[71]
Zhou JS, Pillidge CJ, Gopal PK, et al. Antibiotic susceptibility profiles of new probiotic lactobacillus and Bifidobacterium strains. Int J Food Microbiol 2005; 98(2): 211-7.
[72]
Zhou JS, Shu Q, Rutherfurd KJ, et al. Safety assessment of potential probiotic lactic acid bacterial strains Lactobacillus rhamnosus HN001, L. acidophilus HN017, and Bifidobacterium lactis HN019 in BALB/c mice. Int J Food Microbiol 2000; 56(1): 87-96.
[73]
Rinkinen M, Westermarck E, Salminen S, et al. Absence of host specificity for in vitro adhesion of probiotic lactic acid bacteria to intestinal mucus. Vet Microbiol 2003; 97(1): 55-61.
[74]
Martín R, Langa S, Reviriego C, et al. The commensal microflora of human milk: New perspectives for food bacteriotherapy and probiotics. Trends Food Sci Technol 2004; 15(3): 121-7.
[75]
Vesterlund S, Vankerckhoven V, Saxelin M, et al. Safety assessment of Lactobacillus strains: Presence of putative risk factors in faecal, blood and probiotic isolates. Int J Food Microbiol 2007; 116(3): 325-31.
[76]
De Groote MA, Frank DN, Dowell E, et al. Lactobacillus rhamnosus GG bacteremia associated with probiotic use in a child with short gut syndrome. Pediatr Infect Dis J 2005; 24(3): 278-80.
[77]
Land MH, Rouster-Stevens K, Woods CR, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: A randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 2008; 371(9613): 651-9.
[78]
Cnota J, Shetty AK. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005; 115(1): 178-81.
[79]
Doron SI, Hibberd PL, Gorbach SL. Probiotics for prevention of antibiotic-associated diarrhea. J Clin Gastroenterol 2008; 42: S58-63.
[80]
Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4(1): 44-57.
[81]
Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: What are the risks? Am J Clin Nutr 2006; 83(6): 1256-64.
[82]
Saarela M, Mogensen G, Fonden R, et al. Probiotic bacteria: Safety, functional and technological properties. J Biotechnol 2000; 84(3): 197-215.
[83]
Salminen S, von Wright A, Morelli L, et al. Demonstration of safety of probiotics- A review. Int J Food Microbiol 1998; 44(1): 93-106.
[84]
Charteris WP, Kelly PM, Morelli L, et al. Development and application of an in vitro methodology to determine the transit tolerance of potentially probiotic Lactobacillus and Bifidobacterium species in the upper human gastrointestinal tract. J Appl Microbiol 1998; 84(5): 759-68.
[85]
Ammor MS, Flórez AB, Mayo B. Antibiotic resistance in non-enterococcal lactic acid bacteria and bifidobacteria. Int J Food Microbiol 2007; 24(6): 559-70.
[86]
Ishiwa H, Iwata S. Drug resistance plasmids in Lactobacillus fermentum. J Gen Appl Microbiol 1980; 26(1): 71-4.
[87]
Vescovo M, Morelli L, Bottazzi V. Drug resistance plasmids in Lactobacillus acidophilus and Lactobacillus reuteri. Appl Environ Microbiol 1982; 43(1): 50-6.
[88]
Rinckel LA, Savage DC. Characterization of plasmids and plasmid-borne macrolide resistance from Lactobacillus sp. strain 100-33. Plasmid 1990; 23(2): 119-25.
[89]
Mater DD, Langella P, Corthier G, Flores MJ. A probiotic Lactobacillus strain can acquire vancomycin resistance during digestive transit in mice. J Mol Microbiol 2007; 14(1-3): 123-7.
[90]
Aswathy RG, Ismail B, John RP, et al. Evaluation of the probiotic characteristics of newly isolated lactic acid bacteria. Appl Biochem Biotechnol 2008; 151(2-3): 244-55.
[91]
Ishibashi N, Yamazaki S. Probiotics and safety. Am J Clin Nutr 2001; 73(2): 465s-70s.
[92]
Arora M, Sharma S, Baldi A. Comparative insight of regulatory guidelines for probiotics in USA, India and Malaysia: A critical review. Int J Biotechnol Wellness Ind 2013; 2(2): 51-64.
[93]
Arora M, Baldi A. Regulatory categories of probiotics across the globe: A review representing existing and recommended categorization. Indian J Med Microbiol 2015; 33(5): 2-10.
[94]
Ashish B. Probiotics for health benefits: The regulatory concerns and suggestive roadmap. Biomed J Sci Tech Res 2017; 1(5): 23-4.
[95]
Ashish B. Enforcement of unified global regulatory guidelines for probiotic products: The framework for future. J Forensic Sci & Criminal Inves 2017; 5(1): 555657-8.
[96]
Malika A, Ashish B. Comparative study of regulatory framework for probiotics: Current status and future recommendation. Appl Clin Res Clin Trials Regul Aff 2017; 4(2): 140-56.
[97]
Baldi A. Regulatory and quality concerns for healthcare related products. Appl Clin Res Clin Trials Regul Aff 2017; 4(1): 2-3.
[98]
Malika A, Ashish B. Selective identification and charcterization of potential probiotic strains: A review on comprehensive polyphasic approach. Appl Clin Res Clin Trials Regul Aff 2017; 4(1): 60-76.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 6
ISSUE: 1
Year: 2019
Page: [18 - 33]
Pages: 16
DOI: 10.2174/2213476X06666190126161931

Article Metrics

PDF: 39
HTML: 3
EPUB: 1